MS Pulse is a series of short, engaging reels covering different aspects of multiple sclerosis—from everyday challenges to practical insights. The series is designed to simplify complex topics and support better understanding, conversations, and care in MS.

Health authorities and leading medical societies—from the Gulf region to beyond—now preferentially recommend high-dose influenza vaccination for older adults, driven by robust clinical evidence demonstrating superior protection against influenza-related complications

Leading international health authorities and their affiliated medical associations now recommend age-appropriate influenza vaccination, reflecting a global consensus shaped by robust clinical evidence.

High-Dose Influenza vaccine (HD-IIV) is recommended by different Gulf Health authorities and medical associations for their older adults co-morbid populations

HD-IIV consistently reduced severe hospitalization outcomes compared with SD-IIV regardless of prior history of CVD. Among specific CV outcomes¹, HD-IIV conferred a particularly substantial benefit against hospitalization for HF compared with SD-IIV.¹ Moreover, another prespecified analysis supports the use of HD-IIV for reducing both influenza specific and other hospitalization outcomes in older individuals both with and without preexisting ASCVD, with potentially greater absolute benefit among individuals with ASCVD. ²